Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

November 2015

P&T Committee Updates


At the September 21, 2015 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed two medications and decided the following.

P&T Committee Review and Decisions

Drug Class & Drugs Reviewed 

Description & Drugs Reviewed

Decision

Idiopathic Pulmonary Fibrosis

  • Esbriet (pirfenidone)
  • Ofev (nintedanib) 

Prior to the approval of these two novel agents, there was no effective pharmacological treatment specifically for this disease. Both drugs have a moderate effect on preserving lung function and have common gastrointestinal side effects.

Esbriet (pirfenidone)

  • Added as a Preferred Brand to the Premium and Value formularies
  • Continued coverage on Specialty Tier Medicare Advantage formulary
Ofev (nintedanib)
  • Added as a Preferred Brand to the Premium and Value formularies
  • Continued coverage on Specialty Tier Medicare Advantage formulary

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Medicare Advantage Stride (HMO) Updates and Reminders

Prior Authorizations for Medicare Advantage Stride (HMO) via NIA

Medicare Advantage Stride (HMO) Gender Reassignment Services

New 2016 Medicare Advantage Stride (HMO) Benefits

Hospital Discharge Notifications Reminder

ICD-10 Reminder and Provider Support

HCAS Credentialing Best Practices Guide Now Available

Affordable Care Act and Risk Adjustment

CLINICIAN CORNER

Reminder: Referral Procedure Change for Massachusetts Providers

Identifying and Treating Postpartum Depression

Prior Authorization Required for Rexulti

Prior Authorization Required for Zecuity

P&T Committee Updates

Specialty Pharmacy Program Updates

OFFICE ASSISTANT

Reminder: Keep Panel Status Up to Date

Reminder: Bill National Drug Codes (NDC) For Unlisted Drugs

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator